MDGL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
364.3M
+17.0%
311.3M
-3.0%
321.1M
+11.8%
287.3M
+35.0%
212.8M
Cost of Revenue
0
-100.0%
26.8M
0
0
0
Gross Profit
364.3M
+28.0%
284.5M
-11.4%
321.1M
+11.8%
287.3M
+35.0%
212.8M
Operating Expenses
420.6M
+11.5%
377.2M
-0.9%
380.7M
-5.1%
401.2M
+54.3%
260.0M
R&D
91.2M
-16.1%
108.7M
-6.5%
116.3M
-33.2%
174.0M
+221.7%
54.1M
SG&A
289.4M
+7.8%
268.5M
+11.9%
240.0M
+14.8%
209.1M
+6.2%
196.9M
Operating Income
-56308000
+39.3%
-92723000
-55.6%
-59609000
+47.7%
-113975000
-141.5%
-47202000
EBITDA
-55927000
+39.4%
-92337000
-55.9%
-59217000
+47.9%
-113617000
-142.6%
-46825000
Net Income
-57939000
+38.6%
-94391000
-61.1%
-58575000
+48.7%
-114190000
-170.1%
-42281000
EPS (Basic)
$-1.99
+38.8%
$-3.25
+39.4%
$-5.36
-5.5%
$-5.08
-238.7%
$-1.50
EPS (Diluted)
$-1.99
+38.8%
$-3.25
+39.4%
$-5.36
-5.5%
$-5.08
-238.7%
$-1.50
Shares (Diluted)
29.1M
+0.4%
29.0M
+165.5%
10.9M
-51.4%
22.5M
-20.4%
28.2M
Madrigal Pharmaceuticals (MDGL) โ€” Financials